What is Homogeneous Time-Resolved Fluorescence (HTRF)? HTRF is a hybrid detection technology that combines Förster Resonance Energy...

Learn how ligand binding kinetics reveal hidden drug effects, improve GPCR assay design, and prevent costly errors in drug discovery pipelines.

Early signals can mislead. This week’s Dr. GPCR Weekly shows how to call Mechanism of Action with model-first rigor—distinguishing orthosteric vs. allosteric, designing assays that reveal mechanism, and unlocking SAR. Plus: Novo’s \$550M obesity/diabetes push, Rhythm’s sNDA, key events, and confocal imaging that respects function. Upgrade to Premium for the full digest.

Flow cytometry, a laser-based method, is used to examine single cells suspended in a fluid. By measuring the way these cells scatter...

Turn assay snapshots into predictions. Models separate orthosteric vs allosteric mechanisms and guide experiments for faster decisions in Terry’s Corner.

Ajay Yekkirala’s journey from rejected med student to GPCR biotech founder shows how failure, mentorship, and curiosity can drive real innovation in drug discovery.

Curve shifts can mislead, but statistics won’t. This week in Terry’s Corner: power analysis, t-tests, ANOVA, and F-tests to move from “I think” to “I know.” Plus, Ajay Yekkirala on AI-driven GPCR therapeutics and an invitation to Boston’s GPCR Happy Hour. Premium Members get full access to curated jobs, events, and must-read publications—your edge to stay ahead in fast-moving GPCR science.

Applications of Fluorescent Probes in Confocal Imaging of GPCRs: From Live to Fixed Cells GPCRs are present across cell membranes...

Stop guessing at curve shifts. Learn how t-tests, ANOVA & F-tests bring confidence, not noise, to drug discovery decisions.

Purpose-driven science works because it creates resilience. Careers built on prestige, titles, or external pressure can burn out quickly. But careers built on urgency, alignment, and meaning are the ones that last.

This week’s Dr. GPCR Weekly News delivers urgent insights every GPCR scientist and drug discovery leader needs. From Terry’s Corner on the hidden traps of allosteric binding, to Yamina’s Corner on the hidden costs of fragmented systems, and a preview of Discovery on Target 2025, this edition highlights the frameworks shaping the next decade of therapies. Plus: industry breakthroughs on metabolic GPCRs, key September events, curated career opportunities, and must-read publicat

Join us at the Discovery on Target meeting in Boston for the GPCR Drug Discovery track! I’m honored to chair a session featuring Terry Kenakin, a leader in functional selectivity. We’ll explore GPCR targets like GLP-1R, CXCR4, and dopamine receptors across oncology, metabolic, CNS, and immunology. As Dr. GPCR, we connect scientists and accelerate innovation — see you in Boston!

The ability to identify compounds that interact with molecular targets involved in disease pathways is where the development of new...

At its core, Catherine Demery’s research is about receptors and signaling pathways—how mu-opioid and alpha-2 adrenergic receptors interact to disrupt breathing. But it’s also about public health urgency.

Think you understand ligand displacement? Think again. This week’s Terry’s Corner blog reveals how allosteric modulators reshape receptor identity—and why conventional binding logic fails in these systems.

Catherine Demery shares how walking away from pharmacy school led her to discover a passion for opioid pharmacology. From CRO experience to addiction-focused research, she now investigates fentanyl and xylazine’s effects on respiration using mouse models. Her story offers critical insight into how non-linear paths, personal loss, and public health urgency can shape impactful scientific careers in the GPCR research community.

This week's breakthroughs are crucial for staying ahead in the rapidly evolving landscape of GPCR research and drug discovery. Dr. Terry Kenakin's insights on target residence time can reshape how you evaluate and advance lead compounds, potentially saving your team from costly late-stage failures. That's exactly what Dr. GPCR delivers every week: practical tools and critical intelligence to elevate your science and sharpen your decisions.

Every September, Boston welcomes the global biotech and drug discovery community. Scientists, investors, and CRO professionals fly in from around the world, while Boston’s own vibrant life sciences hub shows up in full force. GPCR Happy Hour is where these two worlds meet. It’s not just networking. It’s where partnerships spark, ideas collide, and the GPCR community grows stronger — together.

A GPCR program can have brilliant science and talented people and still get stuck. The issue isn't a lack of effort; it's a lack of precision. The granular, often overlooked details are where programs falter, leading to unforeseen costs and delays. So, why do promising programs stall despite significant investment and a skilled team?

Most drug discovery teams chase potency, but miss the variable that often determines real-world success: target residence time. In this expert lecture, Dr. Terry Kenakin explores how restricted diffusion, rebinding, and kinetic dissociation transform in vivo pharmacology, especially when PK and PD diverge. If your leads fail in translation, this may be the insight your pipeline needs.

What does it mean to lead in science as a PhD student? In this episode, Alessandro Nicoli reflects on being the first PhD in a new lab, the challenges of delegating, and the rewards of mentoring students. His story reveals how leadership is learned through shared growth, patience, and shaping the next generation of GPCR researchers. A must-read for scientists balancing research with mentoring responsibilities.

In pharmacology, the wrong interpretation of antagonist behavior can derail your conclusions, your experiments, and even your program’s credibility. That’s why mastering competitive vs non-competitive antagonism isn’t optional — it’s essential for accurate, defensible science. This week’s Terry’s Corner takes you beyond curve shapes into the kinetic and mechanistic realities that separate surface-level analysis from true expertise.

Don’t let curve shapes deceive you. In this blog, Dr. Terry Kenakin unpacks why dose-response shifts aren’t definitive proof of antagonist mechanism. Learn how binding kinetics—not just appearance—distinguish competitive from non-competitive antagonism, and why assumptions can mislead drug discovery decisions. If your team relies on DR curves to evaluate receptor blockade, this read will sharpen your approach and help you avoid common pitfalls in mechanism interpretation.

How do you study receptors with no ligands and no structures? In this episode, PhD student Alessandro Nicoli explains how AlphaFold and molecular dynamics are revolutionizing the study of olfactory GPCRs. By turning predictions into starting points, Alessandro and his team are building models that not only match experimental accuracy but also open new doors in ligand discovery, drug design, and the future of computational biology.